NCT04104893 - A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.

Trial Locations (13)

10010

RECRUITING

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York

10468

RECRUITING

James J. Peters VA Medical Center, Bronx, NY, The Bronx

19104

RECRUITING

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia

23249

RECRUITING

Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond

27705

RECRUITING

Durham VA Medical Center, Durham, NC, Durham

33744

RECRUITING

Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines

48105

RECRUITING

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

60612

RECRUITING

Jesse Brown VA Medical Center, Chicago, IL, Chicago

94121

RECRUITING

San Francisco VA Medical Center, San Francisco, CA, San Francisco

98108

RECRUITING

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

90073-1003

RECRUITING

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles

20422-0001

RECRUITING

Washington DC VA Medical Center, Washington, DC, Washington D.C.

97207-2964

RECRUITING

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

VA Office of Research and Development

FED